<DOC>
	<DOCNO>NCT01767376</DOCNO>
	<brief_summary>The purpose study assess immunogenicity , safety reactogenicity meningococcal conjugate vaccine ( MenACWY-TT ) co-administered Boostrix® versus two vaccine give separately healthy adolescent young adult .</brief_summary>
	<brief_title>Immunogenicity Safety Study GlaxoSmithKline ( GSK ) Biologicals ' Meningococcal Conjugate Vaccine ( GSK134612 ) When Co-administered With Boostrix® Subjects Between 11 25 Years Age</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy subject establish medical history clinical examination enter study . Subjects subject ' parent ( ) /Legally Acceptable Representative ( ) [ LAR ( ) ] , opinion investigator , comply requirement protocol . A male female , include , 11 25 year age time first vaccination . Written inform consent obtain subject/from parent ( ) /LAR ( ) subject . Written inform assent obtain subject applicable accord local regulation . Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define premenarche , current tubal ligation , hysterectomy ovariectomy . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period two month completion vaccination series . Child care . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . For corticosteroid , mean prednisone ≥ 10 mg/day , equivalent . Inhaled topical steroid allow . Planned administration/administration vaccine foreseen study protocol period start 30 day first dose vaccine end 30 day last dose vaccine , exception license inactivated influenza vaccine . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Previous vaccination meningococcal vaccine . History meningococcal disease . Vaccination DTPcontaining vaccine within previous five year . History serious allergic reaction follow DTPcontaining vaccine component study vaccine . History encephalopathy within seven day follow administration previous dose pertussis vaccine attributable another identifiable cause . Temperature ≥ 40.5°C ( 105°F ) within 48 hour receipt previous dose DTP vaccine , due another identifiable cause . Collapse shocklike state within 48 hour receipt previous dose DTP vaccine . Seizures without fever within three day previous dose DTP vaccine . Severe Arthustype hypersensitivity reaction follow prior dose tetanus toxoid ( TT ) within previous ten year . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination study period . History reaction hypersensitivity likely exacerbate component vaccine ( ) . Progressive neurologic disorder , uncontrolled epilepsy progressive encephalopathy . History neurologic disorder seizure , include GuillainBarré syndrome ( GBS ) . History simple , single febrile seizure permit . Bleeding disorder , haemophilia thrombocytopenia , subject anticoagulant therapy . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine , plan administration study period . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution . Family history congenital hereditary immunodeficiency . Major congenital defect serious chronic illness . Acute disease and/or fever time enrolment . Fever define temperature ≥ 37.5°C /99.5°F oral , axillary tympanic route . Subjects minor illness ( mild diarrhoea , mild upper respiratory infection ) without fever may enrol discretion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Young adult</keyword>
	<keyword>Adolescents</keyword>
	<keyword>Reactogenicity</keyword>
	<keyword>Diphtheria</keyword>
	<keyword>pertussis</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Meningococcal vaccine</keyword>
	<keyword>Safety</keyword>
	<keyword>Neisseria meningitidis</keyword>
	<keyword>Healthy</keyword>
</DOC>